You are citing phase I data to support an implication that "clearly" phase 3 data was going to be positive. That is not how it works in real life. Many many many drug candidates look great after phase 1 and fail to become approved drugs.
Also, we did double our microfluidic device capacity. We more than doubled it. We increased our capacity by something like a million fold. Before these vaccines (first of their kind), there was no commercial scale capacity. This has all been invented in the last year. There was even a chance that achieving such capacity would not be possible. It is fairly common that drug candidates that look promising in phase 1 or 2 simply cannot be manufactured at scale with the quality required to ensure consistent safety and efficacy.